This database contains 5 studies, archived under the term: "international cooperation"
Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer’s disease
Dubois, Bruno,
Zaim, Mohammed,
Touchon, Jacques,
Vellas, Bruno,
Robert, Philippe,
Murphy, Michael F.,
Pujadas-Navinés, Francesc,
Rainer, Michael,
Soininen, Hilkka,
Riordan, Henry J.,
Kanony-Truc, Claire
New criteria related to prodromal Alzheimer’s disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess […]
Memantine and brain atrophy in Alzheimer’s disease: a 1-year randomized controlled trial
Wilkinson, David,
Fox, Nick C.,
Barkhof, Frederik,
Phul, Ravinder,
Lemming, Ole,
Scheltens, Philip
The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer’s disease (AD) over the course of 52 weeks of treatment with memantine or placebo. This was a multi-national, randomized, double-blind, placebo-controlled, […]
Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial
Scheltens, Philip,
Twisk, Jos W.R.,
Blesa, Rafael,
Scarpini, Elio,
von Arnim, Christine A. F.,
Bongers, Anke,
Harrison, John,
Swinkels, Sophie H. N.,
Stam, Cornelis J.,
de Waal, Hanneke,
Wurtman, Richard J.,
Wieggers, Rico L.,
Vellas, Bruno,
Kamphuis, Patrick J. G. H.
Souvenaid aims to improve synapse formation and function. An earlier study in patients with Alzheimer’s disease (AD) showed that Souvenaid increased memory performance after 12 weeks in drug-naïve patients with mild AD. The Souvenir II study was a 24-week, randomized, controlled, double-blind, parallel-group, multi-country trial to confirm and extend previous findings in drug-naïve patients with […]
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease
Zerr, I.,
Kallenberg, K.,
Summers, D. M.,
Romero, C.,
Taratuto, A.,
Heinemann, U.,
Breithaupt, M.,
Varges, D.,
Meissner, B.,
Ladogana, A.,
Schuur, M.,
Haik, S.,
Collins, S. J.,
Jansen, G. H.,
Stokin, G. B.,
Pimentel, J.,
Hewer, E.,
Collie, D.,
Smith, P.,
Roberts, H.,
Brandel, J. P.,
van Duijn, C.,
Pocchiari, M.,
Begue, C.,
Cras, P.,
Will, R. G.,
Sanchez-Juan, P.
Several molecular subtypes of sporadic Creutzfeldt-Jakob disease have been identified and electroencephalogram and cerebrospinal fluid biomarkers have been reported to support clinical diagnosis but with variable utility according to subtype. In recent years, a series of publications have demonstrated a potentially important role for magnetic resonance imaging in the pre-mortem diagnosis of sporadic Creutzfeldt-Jakob disease. […]
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study
Emre, Murat,
Poewe, Werner,
De Deyn, Peter Paul,
Barone, Paolo,
Kulisevsky, Jaime,
Pourcher, Emmanuelle,
van Laar, Teus,
Storch, Alexander,
Micheli, Federico,
Burn, David,
Durif, Frank,
Pahwa, Rajesh,
Callegari, Francesca,
Tenenbaum, Nadia,
Strohmaier, Christine
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]